News

This review of the latest dermatological studies includes insights on minoxidil in onychodystrophy, teleheath outcomes in HS patients, pediatric AD referrals, and more.

Most AD referrals were low urgency, contributing to prolonged wait times exceeding 30 weeks on average.

AI-analyzed EHRs show a surging burden of hidradenitis suppurativa, chronic urticaria, psoriasis, and eczema, with major comorbidities, costly care, and low biologic use.

Post hoc trial data presented at AAD 2026 show near-clear atopic dermatitis and minimal itch drive bigger gains in quality of life, sleep, mental health, and satisfaction.

A meta-analysis cited in the review found depression prevalence among melasma patients at 43.4% — approximately 12 times the estimated global rate — highlighting the psychiatric weight of pregnancy-associated skin changes.

Building trust through empathetic communication, education, and support resources is essential to improving outcomes for patients with HS.

The study represents a repurposing strategy, using dupilumab as a tool compound to probe whether immune-targeted therapy can address a biologically defined subgroup of MDD.

Interim investigator-initiated trials reveal how Restylane Skinboosters and Sculptra could improve menopausal skin and address GLP-1 weight-loss volume changes.

REZPEG shows growing hair regrowth at 52 weeks in severe alopecia areata, with favorable safety, hinting at a new biologic alternative to JAKs.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on delgocitinib sNDA for pediatric CHE, new 12-month data for clascoterone 5% in androgenetic alopecia, the rise of GLP-1 usage in dermatology, and more.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Meet Andrew C. Krakowski, MD, as he introduces Don't Be Rash and previews the conversations shaping the future of pediatric dermatology.

Kathleen Moe, MD, offers guidance on creating 5-star dermatology patient experience systems for faster access, consistent scripts, and guided checkout that reduce callbacks and build trust.

Pooled phase 3 data show dupilumab rapidly reduces prurigo nodularis activity, cuts excoriations, and boosts healing by week 24 versus placebo.

Dysregulation of the innate immune system, inflammatory cytokines, and abnormal blood vessel growth plays a key role in persistent redness and flushing.

Henry W. Lim, MD, FAAD's legacy highlights the impact of mentorship, research, and global advocacy in advancing inclusive dermatologic care and improving skin health worldwide.

The CHECK-US study found that patients commonly perceive their CHE as driven by overlapping environmental, biological, psychological, and lifestyle factors.

Phase 3 data show clascoterone solution sustains hair regrowth for 12 months with vehicle-like safety, paving the way for a novel male androgenetic alopecia option.

A new gene expression profiling (GEP) test may transform how clinicians select systemic treatments for moderate to severe atopic dermatitis (AD).

A new case-control study found that patients with pemphigus vulgaris and bullous pemphigoid face more than twice the odds of comorbid acute stress disorder compared with matched controls.

Elevated rates of herpes simplex, herpes zoster, and opportunistic infections in the vitiligo cohort underscore infection risk considerations

Spatial transcriptomics reveals how UVB phototherapy calms vitiligo skin, silencing IFN-γ pathways and memory T cells to drive repigmentation.

FDA will review LEO Pharma's delgocitinib cream for adolescent patients aged 12-17 with CHE, backed by phase 3 gains and addressing a major treatment gap.

This review of the latest dermatological studies includes insights on the use of microneedling in wound healing, pediatric HS treatment patterns, the role of blood-related phenotypes in hypertrophic scars and keloids, and more.

A large All of Us cohort analysis found high rates of obesity and depression in both eczema and psoriasis, reinforcing their systemic nature.

A new systematic review shows vitiligo’s stigma-driven mental health and quality-of-life burden varies by culture, urging culturally tailored, multidisciplinary care and education.

Take today's poll and explore real-world VHA data showing delayed, low biologic use in chronic spontaneous urticaria, alongside rising ER, inpatient, and outpatient visits after diagnosis.